Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas

Br J Haematol. 2014 Nov;167(3):430-4. doi: 10.1111/bjh.13001. Epub 2014 Jun 27.
No abstract available

Keywords: elderly; malignant lymphomas; morphology; non-hodgkin lymphoma; prognostic factors.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / immunology
  • Antibodies, Monoclonal, Murine-Derived / pharmacology
  • Antigens, CD20 / analysis
  • Antigens, CD20 / immunology
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Immunoglobulin Light Chains / blood*
  • Immunophenotyping
  • Lymphoma, Large B-Cell, Diffuse / blood*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Male
  • Middle Aged
  • Multicenter Studies as Topic / statistics & numerical data
  • Neoplasm Proteins / blood*
  • Prednisone / administration & dosage
  • Prognosis
  • Randomized Controlled Trials as Topic / statistics & numerical data
  • Rituximab
  • Survival Rate
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Biomarkers
  • Immunoglobulin Light Chains
  • Neoplasm Proteins
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol